CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics 签署 HOA 和谅解备忘录以推进异基因 Gamma Delta T 细胞技术的研究
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學.
总部位于新加坡的生物制药公司CytoMed Therapeutics Limited（纳斯达克股票代码：GDTC）（“CytoMed” 或 “公司”）今天宣布已与CytoMed Therapeutics China Limited（CytoMed China）签订协议负责人（HOA），一家在香港注册成立的公司，与Bionex Solutions Inc. 签订了谅解备忘录（MOU），千叶生命。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。